8-K

                      SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549

                                FORM 8-K

                              CURRENT REPORT

                  PURSUANT TO SECTION 13 OR 15(d) OF THE
                     SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported): May 1, 2007

                            TECHNE CORPORATION
             (Exact Name of Registrant as Specified in Charter)


       Minnesota                     0-17272             41-1427402
(State or Other Jurisdiction       (Commission         I.R.S. Employer
of Incorporation)                  File Number)      Identification No.)

                614 Mckinley Place NE
                   Minneapolis, MN                       55413
       (Address of Principal Executive Offices)       (Zip Code)

     Registrant's telephone number, including area code:  (612) 379-8854

                              Not Applicable
      (Former Name or Former Address, if changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any
of the following provisions:

/ /   Written communications pursuant to Rule 425 under the Securities Act
      17 CFR 230.425)

/ /   Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)

/ /   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

/ /   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))






Item 5.02  Departure of Directors or Principal Officers; Election of
Directors; Appointment of Principal Officers

A copy of the press release issued by Techne Corporation on May 1, 2007,
announcing the appointment of Dr. Richard Krzyzek as Vice President of
its Biotechnology Division and the retirement of Dr. Monica Tsang is
attached hereto as Exhibit 99.1.




Item 9.01 Financial Statements and Exhibits

     (d) Exhibits

         99.1 Press Release dated May 1, 2007.








                            SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Dated: May 1, 2007                    TECHNE CORPORATION
                                      By: /s/ Thomas E. Oland
                                      ---------------------------
                                      Name: Thomas E. Oland
                                      Title: President and Chief
                                        Executive Officer



                          EXHIBIT INDEX

    Exhibit No. Description
    ----------- -----------
       99.1     Press release of Techne Corporation dated May 1, 2007.

EX-99.1

                        TECHNE CORPORATION
                   APPOINTS DR. RICHARD A. KRZYZEK
             VICE PRESIDENT of its BIOTECHNOLOGY DIVISION
                               and
             ANNOUNCES the RETIREMENT of DR. MONICA TSANG


Minneapolis/May 1, 2007/--Techne Corporation (NASDAQ: TECH) today
announced that Richard A. Krzyzek, Ph.D., has been appointed Vice
President of Research for its Biotechnology Division, and that
Dr. Monica Tsang, the Company's Vice President of Research, has
announced her intent to retire effective June 30, 2007.

Dr. Krzyzek joined the R&D Systems, Inc. subsidiary of Techne in
1992.  He has since held several scientific and operational
management positions of increasing responsibility, demonstrating
a commitment to product innovation, product development and
technical competence. Dr. Krzyzek offers a rare blend of
scientific and management strengths and has achieved success
while building the molecular biology, gene expression and
intracellular departments at R&D Systems, Inc.  Prior to his
appointment as Vice President of the Biotechnology Division, Dr.
Krzyzek held the position of Chief Scientific Officer, directing
a staff of over 60 scientists, researchers and laboratory
technicians in the molecular biology, intracellular signaling,
and recombinant protein expression areas, as well as in biotech
administration.

Dr. Krzyzek previously spent 12 years with Molecular Genetics,
Inc., progressing through a series of promotions including those
of Senior and Principal Scientist of Animal Health Research and
as Principal Scientist of both the Nutritional Quality Group and
the Technology Group.  Prior to joining Molecular Genetics, he
served as an Assistant Research Professor in the University of
Minnesota's Department of Microbiology.  Dr. Krzyzek has also
published and co-authored numerous scientific papers and has two
issued patents.

Dr. Krzyzek earned his B.A in biology from Holy Cross College in
Worcester, Massachusetts.  He earned a Ph.D. in microbiology from
the University of Minnesota.

Dr. Tsang has been an employee of R&D Systems since 1985.  She
previously served as Executive Director of Cell Biology for the
Biotechnology Division and, since 1995 has been a Vice President
of the Company.  Dr. Tsang was a co-founding scientist of the
Company's Biotech Division.  Over its history this Division has
produced over 10,000 products and in fiscal 2006 generated almost
$160 million of sales.

Mr. Thomas E. Oland, Techne's Chairman and CEO, said, "We
appreciate Dr. Tsang's service and commitment to R&D Systems over
her many years of leadership.  The Company has substantially
grown during her tenure and is scientifically well positioned.
We are also fortunate to have internally developed a team of
experienced and dedicated employees.  I look forward to working
with Dr. Krzyzek and our talented research scientists to continue
the strategic and operational success that has served our
customers and shareholders."

Forward Looking Statements:
This press release may contain forward-looking statements within
the meaning of the Private Litigation Reform Act. Forward-looking
statements involve risks and uncertainties that may affect the
actual results of operations.  The following important factors,
among others, have affected and, in the future, could affect the
Company's actual results: the introduction and acceptance of new
biotechnology and hematology products, the levels and particular
directions of research by the Company's customers, the impact of
the growing number of producers of biotechnology research
products and related price competition, the retention of
hematology OEM (private label) and proficiency survey business,
the impact of currency exchange rate fluctuations, and the costs
and results of research and product development efforts of the
Company and of companies in which the Company has invested or
with which it has formed strategic relationships.

For additional information concerning such factors, see the
Company's annual report on Form 10-K and quarterly reports on
Form 10-Q as filed with the Securities and Exchange Commission.
We undertake no obligation to update or revise any forward-
looking statements we make in this release due to new information
or future events.  Investors are cautioned not to place undue
emphasis on these statements.

            **********************************************

Techne Corporation has two operating subsidiaries: Research and
Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota
and R&D Systems Europe, Ltd. (R&D Europe) of Abingdon, England.
R&D Systems is a specialty manufacturer of biological products.
R&D Systems has two subsidiaries, Fortron Bio Science, Inc.
(Fortron), located in Minneapolis, and BiosPacific, Inc.
(BiosPacific), located in Emeryville, California.  Fortron
develops and manufactures antibodies and BiosPacific is a
worldwide supplier of biologics to manufacturers of in vitro
diagnostic systems and immunodiagnostic kits.  R&D Europe is a
distributor of biotechnology products.

Contact:   Greg Melsen, Chief Financial Officer
           Kathy Backes, Controller
           (612) 379-8854